Name | 2-(2-methoxyphenyl)-6-methylchromen-4-one |
---|---|
Synonyms |
4H-1-Benzopyran-4-one,2-(2-methoxyphenyl)-6-methyl
2-(2-methoxyphenyl)-6-methyl-4H-chromen-4-one 2-(2-methoxy-phenyl)-6-methyl-chromen-4-one |
Description | 2'MeO6MF is a brain-penetrant positive allosteric modulator at α2β1γ2L and all α1-containing GABAA receptors. 2'MeO6MF also can directly activate α2β2/3 and α2β2/3γ2L GABAA receptors. 2'MeO6MF has anxiolytic and sedative effects. 2'MeO6MF offers neuroprotection and improved functional recovery and dampens the stroke-induced inflammatory response[1][2]. |
---|---|
Related Catalog | |
Target |
GABAA receptor[1] |
In Vitro | 2'MeO6MF (100-300 µM; 60 min) weakly displaces [3H]-flunitrazepam binding to rat brain synaptosomal membranes by 5-10%. 2'MeO6MF enhances [3H]-muscimol binding to rat brain synaptic membranes in a concentration-dependent manner yielding a mean Emax of 219.8% and apparent EC50=20.8 nM[1]. 2'MeO6MF (1-300 µM) enhances the response elicited by a low concentration of GABA in a concentration-dependent manner at recombinant α1β2γ2L GABAA receptors expressed in XenopusM oocytes. 2'MeO6MF enhances the response elicited by GABA at recombinant α1β1,3γ2L and α1β2 GABAA receptors without any direct activation[1]. 2'MeO6MF (1-10 µM; 60 min) increases tonic inhibitory currents in a concentration-dependent manner in granule cells[2]. 2'MeO6MF (100-1000 µM; 6.5 h) inhibits the LPS-induced increase of NFkB activity in RAWblueTM macrophage cells[2]. |
In Vivo | 2'MeO6MF (1-100 mg/kg; i.p.) displays anxiolytic-like effects in the elevated plus maze and light/dark tests. 2'MeO6MF induces sedative effects at higher doses in the holeboard, actimeter and barbiturate-induced sleep time tests[1]. 2'MeO6MF (30 mg/kg; i.p.) increases tonic currents in layer 2/3 pyramidal neurons of mice after stroke[2]. 2'MeO6MF (0.1-30 mg/kg; i.p.) is neuroprotective and enhances functional recovery after focal cerebral ischaemia in mice[2]. Animal Model: Male Balb-c mice (8-10 weeks, 25-35 g)[1] Dosage: 1, 10, 30, 100 mg/kg Administration: I.p. Result: No overt acute toxicity was observed. Exerted anxiolytic effects at low doses and sedative effects at high doses without myorelaxant effects. |
References |
Molecular Formula | C17H14O3 |
---|---|
Molecular Weight | 266.29100 |
Exact Mass | 266.09400 |
PSA | 39.44000 |
LogP | 3.77700 |
~96% 89112-85-6 |
Literature: Kahnberg, Pia; Lager, Erik; Rosenberg, Celia; Schougaard, Jette; Camet, Linda; Sterner, Olov; Nielsen, Elsebet stergaard; Nielsen, Mogens; Liljefors, Tommy Journal of Medicinal Chemistry, 2002 , vol. 45, # 19 p. 4188 - 4201 |
~% 89112-85-6 |
Literature: Mazumdar; Karmakar; Tiwari; Banerjee; Banerji Journal of the Indian Chemical Society, 1990 , vol. 67, # 10 p. 845 - 847 |
~% 89112-85-6 |
Literature: Kahnberg, Pia; Lager, Erik; Rosenberg, Celia; Schougaard, Jette; Camet, Linda; Sterner, Olov; Nielsen, Elsebet stergaard; Nielsen, Mogens; Liljefors, Tommy Journal of Medicinal Chemistry, 2002 , vol. 45, # 19 p. 4188 - 4201 |
~% 89112-85-6 |
Literature: Kahnberg, Pia; Lager, Erik; Rosenberg, Celia; Schougaard, Jette; Camet, Linda; Sterner, Olov; Nielsen, Elsebet stergaard; Nielsen, Mogens; Liljefors, Tommy Journal of Medicinal Chemistry, 2002 , vol. 45, # 19 p. 4188 - 4201 |
~% 89112-85-6 |
Literature: Kahnberg, Pia; Lager, Erik; Rosenberg, Celia; Schougaard, Jette; Camet, Linda; Sterner, Olov; Nielsen, Elsebet stergaard; Nielsen, Mogens; Liljefors, Tommy Journal of Medicinal Chemistry, 2002 , vol. 45, # 19 p. 4188 - 4201 |
~% 89112-85-6 |
Literature: Mazumdar; Karmakar; Rangachari; Banerjee; Banerji Journal of the Indian Chemical Society, 1990 , vol. 67, # 11 p. 911 - 913 |
~% 89112-85-6 |
Literature: Baker; Besly Journal of the Chemical Society, 1940 , p. 1103 |
~% 89112-85-6 |
Literature: Kahnberg, Pia; Lager, Erik; Rosenberg, Celia; Schougaard, Jette; Camet, Linda; Sterner, Olov; Nielsen, Elsebet stergaard; Nielsen, Mogens; Liljefors, Tommy Journal of Medicinal Chemistry, 2002 , vol. 45, # 19 p. 4188 - 4201 |
Precursor 9 | |
---|---|
DownStream 0 |